Market News / Story
Vertex Pharmaceuticals Incorporated (VRTX) Reports Interim ALYFTREK Data in 2–5 Year-Olds
·
Vertex reported interim open-label data at NACFC showing ALYFTREK may restore exocrine pancreatic function in some 2–5 year-old children with CF, enabling PERT discontinuation. ALYFTREK use in this age group is investigational. Material Details #DetailAI Analyst View1Interim OLE data in 2–5 yr-oldsEarly efficacy signal in youngest patients could expand label and patient pool over time.2Some achieved PERT independencePotential reversal of EPI is clinically meaningful and…